Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced its participation in two upcoming investor conferences in August 2024:
1. BTIG Virtual Biotechnology Conference (August 5-6): Adicet Bio will be available for one-on-one meetings.
2. Canaccord Genuity Global Growth Conference (August 13-14, Boston, MA): Chen Schor, President and CEO, will participate in a fireside chat on August 13 at 10:30am ET. A live audio webcast will be available on Adicet Bio's website, with a 30-day replay option.
These conferences provide opportunities for investors to gain insights into Adicet Bio's innovative therapies and future prospects.
Adicet Bio (Nasdaq: ACET), un'azienda biotecnologica in fase clinica focalizzata su terapie allogeniche con cellule T gamma delta per malattie autoimmuni e cancro, ha annunciato la sua partecipazione a due prossime conferenze per investitori ad agosto 2024:
1. BTIG Virtual Biotechnology Conference (5-6 agosto): Adicet Bio sarà disponibile per incontri individuali.
2. Canaccord Genuity Global Growth Conference (13-14 agosto, Boston, MA): Chen Schor, Presidente e CEO, parteciperà a una chiacchierata informale il 13 agosto alle 10:30 ET. Sarà disponibile una diretta audio sul sito web di Adicet Bio, con un'opzione di riproduzione per 30 giorni.
Queste conferenze offrono opportunità agli investitori per ottenere approfondimenti sulle terapie innovative di Adicet Bio e sulle prospettive future.
Adicet Bio (Nasdaq: ACET), una empresa biotecnológica en etapa clínica centrada en terapias con células T gamma delta alogénicas para enfermedades autoinmunes y cáncer, ha anunciado su participación en dos próximas conferencias de inversores en agosto de 2024:
1. BTIG Virtual Biotechnology Conference (5-6 de agosto): Adicet Bio estará disponible para reuniones uno a uno.
2. Canaccord Genuity Global Growth Conference (13-14 de agosto, Boston, MA): Chen Schor, Presidente y CEO, participará en una charla informal el 13 de agosto a las 10:30 a.m. ET. Habrá una transmisión de audio en vivo disponible en el sitio web de Adicet Bio, con una opción de reproducción de 30 días.
Estas conferencias ofrecen oportunidades a los inversores para obtener información sobre las terapias innovadoras de Adicet Bio y sus perspectivas futuras.
Adicet Bio (Nasdaq: ACET)는 자가면역 질환 및 암을 위한 알로겐성 감마 델타 T 세포 치료제에 집중하는 임상 단계의 바이오텍 기업으로, 2024년 8월에 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다:
1. BTIG 가상 생명과학 회의 (8월 5-6일): Adicet Bio는 일대일 미팅을 위해 참석합니다.
2. Canaccord Genuity 글로벌 성장 회의 (8월 13-14일, 보스턴, MA): Chen Schor, 사장 겸 CEO는 8월 13일 오전 10시 30분(ET)에 화로 모임에 참석할 예정입니다. Adicet Bio의 웹사이트에서 실시간 오디오 웹캐스트가 제공되며, 30일 동안 다시 볼 수 있는 옵션이 있습니다.
이 회의들은 투자자들이 Adicet Bio의 혁신적인 치료법과 향후 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Adicet Bio (Nasdaq: ACET), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies par cellules T gamma delta allogéniques pour les maladies auto-immunes et le cancer, a annoncé sa participation à deux conférences pour investisseurs à venir en août 2024 :
1. BTIG Virtual Biotechnology Conference (5-6 août) : Adicet Bio sera disponible pour des réunions individuelles.
2. Canaccord Genuity Global Growth Conference (13-14 août, Boston, MA) : Chen Schor, Président et CEO, participera à une discussion informelle le 13 août à 10h30 ET. Un webinaire audio en direct sera disponible sur le site Web d'Adicet Bio, avec une option de rediffusion de 30 jours.
Ces conférences offrent aux investisseurs l'occasion d'obtenir des informations sur les thérapies innovantes d'Adicet Bio et ses perspectives futures.
Adicet Bio (Nasdaq: ACET), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf allogene Gamma-Delta-T-Zelltherapien für autoimmune Erkrankungen und Krebs spezialisiert hat, hat seine Teilnahme an zwei kommenden Investorenkonferenzen im August 2024 bekannt gegeben:
1. BTIG Virtuelle Biotechnologie-Konferenz (5.-6. August): Adicet Bio steht für persönliche Gespräche zur Verfügung.
2. Canaccord Genuity Global Growth Conference (13.-14. August, Boston, MA): Chen Schor, Präsident und CEO, wird am 13. August um 10:30 Uhr ET an einem „Fireside Chat“ teilnehmen. Eine Live-Audioübertragung wird auf der Website von Adicet Bio verfügbar sein, mit einer 30-tägigen Wiederholungsoption.
Diese Konferenzen bieten Investoren die Möglichkeit, Einblicke in die innovativen Therapien und zukünftigen Perspektiven von Adicet Bio zu erhalten.
- None.
- None.
Details of the events are as follows:
BTIG Virtual Biotechnology Conference, August 5-6, 2024
- The Adicet Bio team will be available for one-on-one meetings during the conference. Please contact your sales representative at BTIG to register for a meeting with the company.
Canaccord Genuity Global Growth Conference, August 13-14, 2024,
- Chen Schor, President and Chief Executive Officer will participate in a fireside chat on August 13, 2024 at 10:30am ET.
The live audio webcast of the Canaccord Genuity fireside chat can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801343072/en/
Adicet Bio., Inc.
Investor and Media Contacts
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Source: Adicet Bio, Inc.
FAQ
What investor conferences will Adicet Bio (ACET) attend in August 2024?
When is Chen Schor's fireside chat at the Canaccord Genuity conference?
How can investors access Adicet Bio's (ACET) presentation at the Canaccord Genuity conference?
What type of therapies is Adicet Bio (ACET) developing?
